Literature DB >> 28371654

Extended low-dose dexamethasone suppression test for diagnosis of atypical Cushing's syndrome in dogs.

K M Fowler1, L A Frank2, F Morandi1, J C Whittemore1.   

Abstract

The purpose of this study was to evaluate extension of the low-dose dexamethasone suppression (LDDS) test from 8 h to 12 h to detect possible hypercortisolemia associated with atypical hyperadrenocorticism (AHAC). Twelve client-owned dogs were enrolled in the study: 6 healthy dogs (group 1) and 6 dogs with suspected AHAC (group 2). Baseline EDTA plasma samples were collected for endogenous ACTH determination using an immunoradiometric assay. Serum samples were collected before and at 4, 8, 10, and 12 h post-administration of 0.01 mg/kg dexamethasone IV for cortisol concentration determination via chemiluminescent assay. Mean endogenous ACTH concentration did not differ between groups (group 1: 22.4 pg/mL, group 2: 20.0 pg/mL; P > 0.2). Mean baseline cortisol concentration also did not differ significantly between groups (group 1: 3.03 μg/dL, group 2: 4.95 μg/dL; P > 0.2) nor was there any difference in mean cortisol concentration between the groups at any other time point (P > 0.2). The cortisol concentration from 1 dog in group 2 suppressed to 0.7 μg/dL at 8 h but increased to 1.5 μg/dL at 10 h and 3.7 μg/dL at 12 h post-dexamethasone. Based on results of this study, use of an extended LDDS test could not differentiate between healthy dogs and dogs with AHAC. Diagnosis of AHAC should continue to be based on prior established criteria until new testing has been identified.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atypical hyperadrenocorticism; Dog; Low-dose dexamethasone suppression test; Occult hyperadrenocorticism

Mesh:

Substances:

Year:  2017        PMID: 28371654     DOI: 10.1016/j.domaniend.2017.03.002

Source DB:  PubMed          Journal:  Domest Anim Endocrinol        ISSN: 0739-7240            Impact factor:   2.290


  3 in total

1.  Successful treatment of occult hyperadrenocorticism with mitotane but not trilostane in a dog.

Authors:  Su-Min Park; Kyeong-Bo Kim; Woo-Jin Song; Hwa-Young Youn
Journal:  Vet Med Sci       Date:  2021-03-23

2.  Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®).

Authors:  Katelin Quantz; Amanda L Anderson; Christine D Harman; Erica L Noland; Jacquelyn M Del Valle; Laurence M Occelli; Jessica B Burn; Simon M Petersen-Jones; Daniel K Langlois; Chris G Pirie; Annette D Petersen; András M Komáromy
Journal:  BMC Vet Res       Date:  2021-12-01       Impact factor: 2.741

3.  ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing's syndrome.

Authors:  Daniel K Langlois; Michele C Fritz; William D Schall; N Bari Olivier; Rebecca C Smedley; Paul G Pearson; Marc B Bailie; Stephen W Hunt
Journal:  BMC Endocr Disord       Date:  2018-05-02       Impact factor: 2.763

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.